EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

Patients with extensive acute myocardial infarctions may develop cardiogenic shock, which has been associated with marked contractile dysfunction due to ischemia. These patients often present with multivessel coronary artery disease.

355 STEMI patients from the DanGer Shock study were analyzed. The inclusion criterion was lactate level ≥2.5 mmol/L and left ventricular ejection fraction ≤45%. Patients in coma were excluded.

This post-hoc analysis evaluated all-cause mortality according to revascularization strategy: culprit-only PCI (VC-PCI, n=118) vs. immediate multivessel PCI (MV-PCI, n=103).

All-cause mortality resulted lower among MV-PCI patients vs. VC-PCI patients (OR 0.65; 95% CI 0.38–1.11). After adjusting for confounding factors, the association was even more significant (OR 0.40; 95% CI 0.19–0.83).

Read also: EuroPCR 2025 | 10-Year Follow-up of DANAMI-3-PRIMULTI: Complete vs. Culprit-Only Revascularization in STEMI with Multivessel Disease.

The authors concluded that, in this subanalysis, immediate complete revascularization (MV-PCI) was associated with reduced 180-day mortality in patients with cardiogenic shock secondary to STEMI. These findings contrast with those of previous landmark trials, such as CULPRIT-SHOCK.

Presented by R. P. Beske during the Major Late Breaking Trials session, EuroPCR 2025, May 21, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...